Risk of New‐Onset Ischaemic and Haemorrhagic Stroke in Patients With Type 2 Diabetes With Chronic Kidney Disease on SGLT‐2 Inhibitor Users: A Population‐Based Cohort Study

Documenti analoghi

• Comparison of SGLT2 Inhibitors for New‐Onset Proteinuria Risk in Patients With Type 2 Diabetes and Preserved Kidney Function
  di: Hiroki Nobayashi, et al.
  Pubblicazione: (2026)
• Association of SGLT2 Inhibitor With Stroke in Type 2 Diabetes With Diabetic Retinopathy: A Multicenter Electronic Health Record Data Study
  di: Kuo‐En Chen, et al.
  Pubblicazione: (2026)
• Adding Finerenone to SGLT2 Inhibitors and Long‐Term Kidney Outcomes in Diabetic Kidney Disease
  di: Masaru Matsui, et al.
  Pubblicazione: (2026)
• Effect of SGLT2 Inhibitors + DPP‐4 Inhibitors on Urine Microbiota in Type 2 Diabetes
  di: Marco Calvigioni, et al.
  Pubblicazione: (2026)
• Discontinuation of SGLT2i After a Urogenital Infection: A Population‐Based Matched Cohort Study of Patients With Type 2 Diabetes
  di: Christine Ljungberg, et al.
  Pubblicazione: (2026)